Sustained benefit seen for etranacogene dezaparvovec in hemophilia B

For men with hemophilia B, receipt of gene therapy comprising an infusion of etranacogene dezaparvovec results in sustained endogenous factor IX expression and low annualized bleeding rates over five years, according to a study published online…

Continue Reading

News Source: medicalxpress.com